In order to corroborate the anti-inflammatory effects of LRRK2 inhibition in preclinical models of AD- and PD-related neuroinflammation, we first generated and validated Aβ1-42 and α-syn fibrils for intracerebral injection (Figure 1). Here, LRRK2 is linked to Parkinson disease.